Joe Kunkle's  Instablog

Joe Kunkle
Send Message
History/Trading Style: I have been trading for 12 years, since I was 15, and have studied a variety of trading techniques and strategies. I combine many trading philosophies and combine technical analysis, fundamental analysis, and macro-economic analysis into every trade. I mostly trade options... More
My company:
Options Hawk
My blog:
Options Hawk
  • Vanda Pharmaceuticals (VNDA): Tomorrow's Headline Stock 0 comments
    May 6, 2009 7:17 PM | about stocks: VNDA, GSK, JNJ, PFE, LLY, BMY, AZN

     After the close the FDA announced the approval of Vanda (NASDAQ:VNDA) Fanapt, an anti psychotic drug for treatment of schizophrenia, sending share 800% higher in after hours trading, from $1 to $9.70.

    Vanda (VNDA) shares were trading at 0.68x cash value, and I wish I had known the PDUFA data was 5/6 because the opportunity was glaring.

    This is a potential giant market for Vanda if it can steal market share, and also makes Vanda a likely takeover target for a large Pharma. At more than a $15 billion market in 2007 and growing faster than many other markets, if Vanda can steal just 10% of this market, it makes for $1.5 billion in sales, and with 26.7 million shares outstanding, Vanda would price around $56, $28 if it takes just 5% of sales.  

    By 2012, 4 of the top 6 drugs lose patents, making room for generic competition, although if Vanda's drug can show less side effects, we could see it dominate the market.

    Vanda is not a one hit wonder, and has Tasimelteon in the pipeline for the treatment of sleep disorders.  Vanda has 5 Analysts covering it and I expect a multitude of upgrades to come.  Shares were at $32.50 in early 2007 and I see no reason why shares cannot return to that level.  Tang Capital recently called for liquidation of the company, and it will be interesting to see how that shakes out, as Tang can probably find a buyer for the firm now with a much higher value on a potential discounted cash flow basis.

    You can also short some of the other names in sympathy, especially JNJ which is having issues with the FDA and its drug. Schering Plough (SGP) also has a drug in the pipeline, Saphris, and could see selling.

    View of the market:


    Disclosure: I own VNDA Shares







    Stocks: VNDA, GSK, JNJ, PFE, LLY, BMY, AZN
Back To Joe Kunkle's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


  • What are Your Options for Options?
    Nov 6, 2010
  • Follow @OptionRadar on Twitter for timely updates - do not like how links post from this Stock Talk now
    Oct 1, 2010
  • $CDE into the clear
    Sep 22, 2010
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.